Skip to content

Enterprise value at other companies

Pfizer logo
PfizerPFE
$222.4B+9.2%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
$1B+982%
Replimune Group logo
Replimune GroupREPL
$717.02M-14.3%
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
$2.8B+110%
Erasca, Inc. logo
Erasca, Inc.ERAS
$5.03B+1,265%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$2.62B+275%

Other financials

Income statement

See full
Revenue-
Operating income-$15.6M+8.1%
Net income-$15.2M+4.8%
EPS (diluted)-$1.11+6.7%

Balance sheet

See full
Cash & equivalents$192.1M+98.7%
Total debt$409.0K-57.2%
Total equity$184.4M+103%
Total assets$198.7M+98.9%

Cash flow

See full
Operating cash flow-$12.9M+7.6%
CapEx$5.0K-72.2%
Free cash flow-$12.9M+7.7%

Valuation

See full
Market cap$184.2M+72.6%

Returns & leverage

See full
Return on equity-42.7%
Debt / equity0.0×
Current ratio13.8×+2.6×

Where this comes from

Calculated from OnKure Therapeutics, Inc.’s reported figures.

The official record: OnKure Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about OnKure Therapeutics, Inc.'s enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is OnKure Therapeutics, Inc.'s enterprise value?
OnKure Therapeutics, Inc. (OKUR) reported enterprise value of -$13.45M in Q1 2026.
How has OnKure Therapeutics, Inc.'s enterprise value changed year-over-year?
OnKure Therapeutics, Inc.'s enterprise value decreased by 115.6% year-over-year, from $86.21M to -$13.45M.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.